Vitiligo Successfully Treated With Roflumilast Cream 0.3.

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Vitiligo is an autoimmune disorder causing skin depigmentation.
• It significantly impacts patients' quality of life, particularly those with darker skin tones.
• Conventional treatments often yield unsatisfactory results for some patients.

Purpose of the Study:

• To report a case of vitiligo treatment in a patient with skin of color.
• To evaluate the efficacy of roflumilast cream 0.3% in a non-responsive vitiligo case.
• To explore potential therapeutic effects of roflumilast for refractory vitiligo.

Main Methods:

• A case study design was employed.
• An adult patient with vitiligo and skin of color received roflumilast cream 0.3%.
• The patient had previously shown poor response to standard vitiligo treatments.

Main Results:

• The patient experienced almost complete repigmentation on the forehead and cheeks.
• Roflumilast cream 0.3% demonstrated a positive therapeutic outcome.
• The treatment was effective in a case resistant to conventional therapies.

Conclusions:

• Roflumilast cream 0.3% may be a viable treatment option for vitiligo.
• It shows potential benefit for patients unresponsive to other therapies.
• Further investigation into roflumilast for vitiligo is warranted, especially for skin of color.